Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.48 EUR | +1.64% | -8.15% | +2.90% |
04-22 | BioXcel Therapeutics to Launch At-Home Trial of Potential Bipolar, Schizophrenia Agitation Treatment | MT |
04-11 | Gerresheimer shares down on outlook, but key contracts confirmed | RE |
Sales 2024 * | 77.05M 83.83M 114M | Sales 2025 * | 80.35M 87.42M 119M | Capitalization | 35.59M 38.72M 52.73M |
---|---|---|---|---|---|
Net income 2024 * | -1M -1.09M -1.48M | Net income 2025 * | - 0 0 | EV / Sales 2024 * | 0.59 x |
Net Debt 2024 * | 9.8M 10.66M 14.52M | Net Debt 2025 * | 6.7M 7.29M 9.93M | EV / Sales 2025 * | 0.53 x |
P/E ratio 2024 * |
-26.1
x | P/E ratio 2025 * |
-124
x | Employees | 1,071 |
Yield 2024 * |
2.42% | Yield 2025 * |
3.43% | Free-Float | 100% |
1 day | +1.64% | ||
1 week | -8.15% | ||
Current month | -0.80% | ||
1 month | -5.34% | ||
3 months | +3.33% | ||
6 months | -9.16% | ||
Current year | +2.90% |
Managers | Title | Age | Since |
---|---|---|---|
Kimmo Herranen
CEO | Chief Executive Officer | 51 | 04-12-31 |
Kalle Lehtonen
DFI | Director of Finance/CFO | 50 | 23-07-31 |
Director/Board Member | 54 | 93-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Risto Koivula
BRD | Director/Board Member | 56 | 21-08-15 |
Chairman | 58 | 18-06-30 | |
Director/Board Member | 56 | 22-04-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-15 | 2.48 | +1.64% | 6,067 |
24-05-14 | 2.44 | -2.40% | 5,726 |
24-05-13 | 2.5 | -0.79% | 810 |
24-05-10 | 2.52 | -6.67% | 5,994 |
24-05-08 | 2.7 | +8.00% | 4,639 |
Delayed Quote Nasdaq Helsinki, May 15, 2024 at 08:39 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.90% | 38.68M | |
+9.92% | 7.42B | |
-13.33% | 291M | |
-.--% | 62.2M |
- Stock Market
- Equities
- ADMIN Stock